Parkinson's syndrome and Parkinson's disease in mitochondrial disorders
Identifieur interne : 000201 ( Main/Exploration ); précédent : 000200; suivant : 000202Parkinson's syndrome and Parkinson's disease in mitochondrial disorders
Auteurs : Josef Finsterer [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-04.
English descriptors
- KwdEn :
Abstract
In the majority of cases, mitochondrial disorders are multisystem conditions that most frequently affect the skeletal muscle, followed by the central nervous system. One of the clinical manifestations of central nervous system involvement is Parkinson's syndrome (PS). Evidence for an association of mitochondrial defects with PS comes from mitochondrial disorder patients who have developed Parkinson's syndrome and from Parkinson's syndrome patients who have developed a mitochondrial disorder. In addition, there are a number of patients with Parkinson's syndrome or Parkinson's disease (PD) who later develop subclinical immunohistological or biochemical indications of mitochondrial defects or accumulates mitochondrial DNA mutations within various cerebral regions. There are also Parkinson's syndrome patients who present with elevated cerebrospinal‐fluid lactate by magnetic resonance spectroscopy. Furthermore, it has been shown that mutations in genes causing PD, such as PINK1, parkin, DJ1, alpha‐synuclein, and LRRK2, also cause mitochondrial dysfunction, which is one of the reasons why they are called mitochondrial nigropathies. Parkinson's syndrome in patients with a mitochondrial disorder may also result from oxidative stress or exogenous toxins. Treatment of mitochondrial Parkinson's syndrome is not at variance with the treatment of Parkinson's syndrome due to other causes, but because of the multisystem nature of mitochondrial disorders, mitochondrial Parkinson's syndrome requires additional therapeutic support. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23651
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's syndrome and Parkinson's disease in mitochondrial disorders</title><author><name sortKey="Finsterer, Josef" sort="Finsterer, Josef" uniqKey="Finsterer J" first="Josef" last="Finsterer">Josef Finsterer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5FC1284DBD9D2B8CC6C8A5D6A22B90803D01B02A</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23651</idno><idno type="url">https://api.istex.fr/document/5FC1284DBD9D2B8CC6C8A5D6A22B90803D01B02A/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000159</idno><idno type="wicri:Area/Main/Curation">000130</idno><idno type="wicri:Area/Main/Exploration">000201</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's syndrome and Parkinson's disease in mitochondrial disorders</title><author><name sortKey="Finsterer, Josef" sort="Finsterer, Josef" uniqKey="Finsterer J" first="Josef" last="Finsterer">Josef Finsterer</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Krankenanstalt Rudolfstiftung, Vienna, Danube University, Krems</wicri:regionArea><wicri:noRegion>Krems</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-04">2011-04</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="784">784</biblScope><biblScope unit="page" to="791">791</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">5FC1284DBD9D2B8CC6C8A5D6A22B90803D01B02A</idno><idno type="DOI">10.1002/mds.23651</idno><idno type="ArticleID">MDS23651</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>extrapyramidal disease</term><term>genetics</term><term>metabolic disease</term><term>mitochondrial DNA</term><term>mitochondrial myopathy</term><term>neurodegenerative disorder</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the majority of cases, mitochondrial disorders are multisystem conditions that most frequently affect the skeletal muscle, followed by the central nervous system. One of the clinical manifestations of central nervous system involvement is Parkinson's syndrome (PS). Evidence for an association of mitochondrial defects with PS comes from mitochondrial disorder patients who have developed Parkinson's syndrome and from Parkinson's syndrome patients who have developed a mitochondrial disorder. In addition, there are a number of patients with Parkinson's syndrome or Parkinson's disease (PD) who later develop subclinical immunohistological or biochemical indications of mitochondrial defects or accumulates mitochondrial DNA mutations within various cerebral regions. There are also Parkinson's syndrome patients who present with elevated cerebrospinal‐fluid lactate by magnetic resonance spectroscopy. Furthermore, it has been shown that mutations in genes causing PD, such as PINK1, parkin, DJ1, alpha‐synuclein, and LRRK2, also cause mitochondrial dysfunction, which is one of the reasons why they are called mitochondrial nigropathies. Parkinson's syndrome in patients with a mitochondrial disorder may also result from oxidative stress or exogenous toxins. Treatment of mitochondrial Parkinson's syndrome is not at variance with the treatment of Parkinson's syndrome due to other causes, but because of the multisystem nature of mitochondrial disorders, mitochondrial Parkinson's syndrome requires additional therapeutic support. © 2011 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Finsterer, Josef" sort="Finsterer, Josef" uniqKey="Finsterer J" first="Josef" last="Finsterer">Josef Finsterer</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000201 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000201 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5FC1284DBD9D2B8CC6C8A5D6A22B90803D01B02A
|texte= Parkinson's syndrome and Parkinson's disease in mitochondrial disorders
}}
| This area was generated with Dilib version V0.6.23. |  |